Fairvalue-Calculator Fairvalue-Calculator
EN DE

C&R Research Inc (359090) Fair Value & Analysis

Healthcare · KR · Market cap 31.6B KRW

Price550.00 KRW
Fair Value643.84 KRW
Upside+17.1%
Quality92/100
Evidence: High Range 472.38 KRW – 787.31 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

C&R Research Inc (359090) currently trades at 550.00 KRW, while our model-based Fair Value estimate is 643.84 KRW — implying the stock looks roughly 17.1% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company's therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -35% Pro Medicus Limited (PME) -86% BrightSpring Health Services, Inc (BTSG) -68% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -33% M3, Inc (MTHRY) +43%

Frequently asked questions

Is C&R Research Inc (359090) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 643.84 KRW versus a price of 550.00 KRW — about +17% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 359090?
Our 21-model fair value for C&R Research Inc is 643.84 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 550.00 KRW.
What is the quality score of 359090?
C&R Research Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.